Guideline Acute Promyelocytic Leukemia ( APL )

[1]  R. Larson,et al.  Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. , 2010, Blood.

[2]  M. Vignetti,et al.  Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group. , 2010, Blood.

[3]  H. Dombret,et al.  Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experience. , 2009, Blood.

[4]  W. Hiddemann,et al.  High dose ara-C in the treatment of newly diagnosed acute promyelocytic leukemia: long-term results of the German AMLCG , 2009, Leukemia.

[5]  F. Lo‐Coco,et al.  Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  H. Dombret,et al.  Impact of ATRA Duration during the Induction Treatment of Newly Diagnosed APL , 2008 .

[7]  J. Esteve,et al.  Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. , 2008, Blood.

[8]  H. Dombret,et al.  Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA results. , 2008, Blood.

[9]  D. Grimwade,et al.  The Management of Acute Promyelocytic Leukemia Presenting During Pregnancy , 2007 .

[10]  T. Büchner,et al.  Arsentrioxid : ein erfolgreiches Gift bei Patienten mit akuter Promyelozytenleukämie , 2007 .

[11]  H. Dombret,et al.  Is cytarabine useful in the treatment of acute promyelocytic leukemia? Results of a randomized trial from the European Acute Promyelocytic Leukemia Group. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  S. Fröhling,et al.  High-dose cytarabine and mitoxantrone in consolidation therapy for acute promyelocytic leukemia , 2005, Leukemia.

[13]  R. Patnaik.  Risk-adapted Treatment of Acute Promyelocytic Leukemia with all-trans-retinoic Acid and Anthracycline Mono Chemotherapy : A Multicenter Study by the PETHEMA Group , 2005, Indian Journal of Medical and Paediatric Oncology.

[14]  J. Esteve,et al.  Therapy-related acute promyelocytic leukemia. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  S. Soignet,et al.  United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  F. Birg,et al.  Characterization of acute promyelocytic leukemia cases lacking the classic t(15;17): results of the European Working Party. Groupe Français de Cytogénétique Hématologique, Groupe de Français d'Hematologie Cellulaire, UK Cancer Cytogenetics Group and BIOMED 1 European Community-Concerted Action "Mole , 2000, Blood.

[17]  J. Esteve,et al.  From bloodjournal.hematologylibrary.org at PENN STATE UNIVERSITY on February 23, 2013. For personal use , 2000 .

[18]  H. Dombret,et al.  Long-term follow-up confirms the benefit of all-trans retinoic acid in acute promyelocytic leukemia , 2000, Leukemia.

[19]  G. Jackson,et al.  The incidence of acute promyelocytic leukemia appears constant over most of a human lifespan, implying only one rate limiting mutation , 2000, Leukemia.

[20]  S J Chen,et al.  Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. , 1999, Blood.

[21]  D. Grimwade,et al.  CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Presenting White Blood Cell Count and Kinetics of Molecular Remission Predict Prognosis in Acute Promyelocytic Leukemia Treated With All- Trans Retinoic Acid: Result of the Randomized MRC Trial , 2022 .

[22]  C. Bloomfield,et al.  All-trans-retinoic acid in acute promyelocytic leukemia. , 1997, The New England journal of medicine.

[23]  P. Fenaux,et al.  Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. European APL 91 Group , 1993 .

[24]  J. Rowley,et al.  15/17 TRANSLOCATION, A CONSISTENT CHROMOSOMAL CHANGE IN ACUTE PROMYELOCYTIC LEUKAEMIA , 1977, The Lancet.

[25]  R. Arceci.  Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome , 2010 .

[26]  E. Estey,et al.  Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  S. Shi.  Use of Arsenic Trioxide in the Treatment of Acute Promyelocytic Leukemia , 2002 .

[28]  H. Dombret,et al.  Long-term follow-up confirms the benefit of all-trans retinoic acid in acute promyelocytic leukemia. European APL group. , 2000, Leukemia.

[29]  P. Pandolfi,et al.  Acute promyelocytic leukemia: from genetics to treatment. , 1994, Blood.